Literature DB >> 26924092

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

Arun J Sanyal1, Veronica Miller2.   

Abstract

Entities:  

Keywords:  Alcoholic Hepatitis; Clinical Trials; Drug Approval; Drug Development; End Points; Nonalcoholic Steatohepatitis; Regulatory Science; Trial Design

Mesh：

Year:  2016        PMID： 26924092      PMCID： PMC6802739          DOI： 10.1053/j.gastro.2016.02.044

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  17 in total

Review 1.  Alcoholic hepatitis: Prognosis and treatment.

Authors:  Jennifer Casanova; Ramón Bataller
Journal:  Gastroenterol Hepatol       Date:  2014-03-20       Impact factor: 2.102

2.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

3.  Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.

Authors:  Arun J Sanyal; Bin Gao; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2015-05-23       Impact factor: 22.682

4.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

Authors:  Michael R Charlton; Justin M Burns; Rachel A Pedersen; Kymberly D Watt; Julie K Heimbach; Ross A Dierkhising
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

5.  A histologic scoring system for prognosis of patients with alcoholic hepatitis.

Authors:  José Altamirano; Rosa Miquel; Aezam Katoonizadeh; Juan G Abraldes; Andrés Duarte-Rojo; Alexandre Louvet; Salvador Augustin; Rajeshwar P Mookerjee; Javier Michelena; Thomas C Smyrk; David Buob; Emmanuelle Leteurtre; Diego Rincón; Pablo Ruiz; Juan Carlos García-Pagán; Carmen Guerrero-Marquez; Patricia D Jones; A Sidney Barritt; Vicente Arroyo; Miquel Bruguera; Rafael Bañares; Pere Ginès; Juan Caballería; Tania Roskams; Frederik Nevens; Rajiv Jalan; Philippe Mathurin; Vijay H Shah; Ramón Bataller
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

6.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

7.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

8.  Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.

Authors:  Alexandre Louvet; Faustine Wartel; Hélène Castel; Sébastien Dharancy; Antoine Hollebecque; Valérie Canva-Delcambre; Pierre Deltenre; Philippe Mathurin
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

Review 9.  Alcoholic hepatitis: current challenges and future directions.

Authors:  Ashwani K Singal; Patrick S Kamath; Gregory J Gores; Vijay H Shah
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-28       Impact factor: 11.382

10.  Alcoholic hepatitis.

Authors:  Thomas Damgaard Sandahl
Journal:  Dan Med J       Date:  2014-10       Impact factor: 1.240
View more
  6 in total

1.  Pharmacologic Management of Nonalcoholic Steatohepatitis.

Authors:  Brent A Neuschwander-Tetri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-10

2.  Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.

Authors:  Yan Wang; Robert Vincent; Jinlian Yang; Amon Asgharpour; Xieer Liang; Michael O Idowu; Melissa J Contos; Kalyani Daitya; Mohammed S Siddiqui; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

3.  Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.

Authors:  Arun J Sanyal; Philippe Mathurin; Laura A Nagy
Journal:  Gastroenterology       Date:  2016-05-04       Impact factor: 22.682

Review 4.  Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Authors:  Rosa Lombardi; Simona Onali; Douglas Thorburn; Brian R Davidson; Kurinchi Selvan Gurusamy; Emmanuel Tsochatzis
Journal:  Cochrane Database Syst Rev       Date:  2017-03-30

5.  Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.

Authors:  Munkhzul Ganbold; Yohei Owada; Yusuke Ozawa; Yasuhiro Shimamoto; Farhana Ferdousi; Kenichi Tominaga; Yun-Wen Zheng; Nobuhiro Ohkohchi; Hiroko Isoda
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

Review 6.  Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

Authors:  James J Connolly; Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2018-06-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.